Open Access Pub publishes peer-reviewed, free-to-read open-access articles. Showing
articles matching anti-depressant — open any to read the full text,
or download the PDF or XML.
Nov 2020 DOI 10.14302/issn.2470-5020.jnrt-20-3596
Kombate DamelanCorresponding author
University of Kara (Togo)
Background Reversible posterior encephalopathy syndrome (RPE) is a clinical and radiological entity characterized by the acute or subacute fitting of symptoms covering headache, vomiting, visual disturbances, seizures and impairment of consciousness. The pathophysiology of RPE syndrome is poorly described. RPE syndrome is characterized by a reversible cerebral edema of often posterior topography in magnetic resonance imagery (MRI). Cases Presentation We consider RPE syndrome four cases under various conditions that are known as airplane flight, hypertension, non-steroidal anti-inflammatory medication, pregnancy and oldness with several pathologies. The RPE was described with several symptoms like headaches, vomiting, focal motor deficit, paresthesia, seizures, disorders of consciousness and photophobia. The imagery findings were varying from cortical hypersignals in Flair sequences to edema of both cortex and sub cortex. The outcome was good with a complete regression of symptoms and imagery lesions. Conclusion The pathophysiological mechanism of RPE syndrome remains unknown. High blood pressure, renal failure and drugs (anti-depressants, NSAIDs, immunosuppressants) are the most etiological factors. The diagnosis is based on clinical arguments and brain MRI. The main location is posterior. The clinical outcome was good with all the patients in our study, no recurrence was noted.
Aug 2017 DOI 10.14302/issn.2476-1710.jdt-17-1673
Li ShupengCorresponding author
School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China
Ketamine’s potential as a fast-acting reagent to treat MDD, especially treatment-resistant depression has caught much attention recently. Although much has been learned about the biological mechanisms underlying ketamine’s effect, there are a few critical issues remained to be resolved. This mini review will briefly discuss several controversial issues that warrant further studies, regarding the molecular, physiological, psychopharmacological, and behavioral effects of ketamine. Understand how ketamine works as an anti-depressant will open the door to better understanding of MDD and its treatment.
Jul 2016 DOI 10.14302/issn.2474-9273.jbtm-15-817
Liu JianCorresponding author
Brock University, Ontario, Canada
Objective: To examine whether having metabolic syndrome (MS) among seniors is associated with using anti-depression medication. Methods: A total of 1366 (617 men and 749 women) individuals aged 60+ years from the NHANES 2007/08 survey who had no reported heart disease and/or cancers but had information on prescribed medications in previous month were included in this analysis. All subjects were categorized into three prescribed drug use status, ie, none (group 1); no anti-depressants (group 2); and with anti-depressants (group 3). MS was defined with the criteria of the ATP III. Results: Over 80% of individuals reported taking prescribed medications with 6% of men and 16% of women respectively having used anti-depressants. About 36% of men and 40% of women respectively were considered to have MS. Results from multiple logistic regression analyses indicated that in comparing to group 1, the odds ratios (95% CI) of MS was 2.73 (1.96, 3.82) for group2 and 2.25 (1.07, 4.69) for group 3, respectively. Both group 2 and 3 had a similar metabolic risk profile, in comparing to group 1, they had higher odds of having diabetes and high level of blood pressures. Conclusion: Seniors with medications are more likely to be with MS, diabetes, and high level blood pressures. However, the observed the cardio-metabolic risk association seems similar between seniors using anti-depressant drugs and using other prescribed medications.